Key result
Aspirin at concentrations ≥250 microM augmented U46619-induced human platelet aggregation and ATP release via secreted ADP and subsequent P2Y12/Gi related signaling.
Why the study?
Does aspirin augment U46619-induced platelet aggregation in human platelets?
Does aspirin augment U46619-induced platelet aggregation in human platelets?
Aspirin paradoxically augments U46619-induced platelet aggregation via secreted ADP and P2Y12/Gi related signaling.
Answers are grounded in this paper and cite their sources.
High-dose aspirin may paradoxically enhance platelet responses in vitro; leaves open clinical relevance and requires in vivo validation.
Aspirin is known to suppress platelet function markedly. However, aspirin at concentrations higher than 1 mM was observed to augment 1.3 microM U46619 (a stable thromboxane receptor (TP receptor) agonist) induced human platelet aggregation in this study. Moreover, at a concentration as low as 250 microM aspirin increased the aggregation induced by U46619 in 13% of normal and healthy individuals. The degree of platelet aggregation and the amount of ATP release were enhanced in U46619 stimulated platelet rich plasma by the addition of aspirin (>250 microM). U46619 was previously reported to inhibit forskolin-stimulated adenyl cyclase and to reduce the cAMP formation. Both of the augmentation effects of aspirin on U46619-induced aggregation and ATP release were blocked by MeSAMP, a P2Y(12) receptor antagonist. U46619 induced aggregation was suppressed by the addition of ADP scavenger (CP/CPK) with no significant change on ATP measured and the effect of CP/CPK could not be reversed by aspirin. In addition, aspirin augmented the inhibitory effect of U46619 on the cAMP production. Our present results suggested that the potentiation effect of aspirin on U46619 induced aggregation was related with the secreted ADP and the subsequent P2Y(12)/Gi related signaling.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2009) studied Healthy individuals (in vitro platelet function). Aspirin vs. U46619 alone was evaluated on U46619 induced human platelet aggregation. Aspirin at concentrations ≥250 microM augmented U46619-induced human platelet aggregation and ATP release via secreted ADP and subsequent P2Y12/Gi related signaling.
Synapse has enriched 10 related papers. Consider them for comparative context: